Laffer Investments trimmed its position in shares of Humana Inc (NYSE:HUM) by 6.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,090 shares of the insurance provider’s stock after selling 660 shares during the period. Laffer Investments’ holdings in Humana were worth $2,215,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. WFG Advisors LP grew its holdings in Humana by 4.5% during the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after purchasing an additional 20 shares during the period. Cadence Capital Management LLC grew its holdings in Humana by 0.4% during the second quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock valued at $1,367,000 after purchasing an additional 22 shares during the period. Financial Advisors Network Inc. grew its holdings in Humana by 3.4% during the second quarter. Financial Advisors Network Inc. now owns 1,413 shares of the insurance provider’s stock valued at $340,000 after purchasing an additional 46 shares during the period. Nordea Investment Management AB grew its holdings in Humana by 1.0% during the second quarter. Nordea Investment Management AB now owns 7,338 shares of the insurance provider’s stock valued at $1,766,000 after purchasing an additional 74 shares during the period. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in Humana by 4.6% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 2,095 shares of the insurance provider’s stock valued at $504,000 after purchasing an additional 92 shares during the period. 94.19% of the stock is owned by institutional investors and hedge funds.
Humana Inc (NYSE HUM) opened at $256.24 on Thursday. Humana Inc has a twelve month low of $186.25 and a twelve month high of $264.56. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61. The company has a market capitalization of $36,377.89, a price-to-earnings ratio of 21.73, a PEG ratio of 1.75 and a beta of 0.88.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. During the same period last year, the company earned $3.18 earnings per share. The business’s revenue for the quarter was down 3.0% on a year-over-year basis. research analysts anticipate that Humana Inc will post 11.63 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.62%. Humana’s dividend payout ratio (DPR) is presently 12.59%.
Several brokerages have weighed in on HUM. Cowen reissued a “buy” rating and set a $285.00 price objective on shares of Humana in a report on Wednesday. Cantor Fitzgerald reissued a “hold” rating and set a $230.00 price objective on shares of Humana in a report on Tuesday, December 5th. Credit Suisse Group reduced their price objective on Humana from $256.00 to $246.00 and set a “neutral” rating for the company in a report on Friday, November 10th. BMO Capital Markets increased their price objective on Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, November 10th. Finally, Morgan Stanley reduced their price objective on Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a report on Thursday, November 9th. Twelve research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $256.30.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.